Skip to main content

Noncystic Fibrosis Bronchiectasis (NCFB)

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT04643587 | PHASE 1 | INTERVENTIONAL

This study is a prospective, multicenter, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory efficacy of nebulized CSL787 after administrations of single (SAD) ascending doses in healthy subjects and multiple (MAD) ascending doses in subjects with NCFB.

Trial Information
3 Sites
64 Participants
Recruiting
18 Years to 45 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

IKF Pneumologie Institute
Frankfurt,Germany
Medicines Evaluation Unit (MEU)
Manchester,England,United Kingdom,M239QZ
Celerion
Belfast,Northern Ireland,United Kingdom,BT96AD

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov